Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Jeffery J. Auletta, Megan M. Herr et al.|Blood Advances|2025Cited by 16
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphomaKitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee et al.|Hematological Oncology|2019Cited by 13
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study GroupKitsada Wudhikarn, Tanin Intragumtornchai, Udomsak Bunworasate et al.|Journal of Geriatric Oncology|2019Cited by 7
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registryTanin Intragumtornchai, Kitsada Wudhikarn, Udomsak Bunworasate et al.|Annals of Hematology|2016Cited by 6
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysisHemalatha G. Rangarajan, Jeffery J. Auletta, Prakash Satwani et al.|Blood Advances|2025Cited by 5